

Product News

Free October Webinar: **Genome Editing Using Nucleofector™ Technology**

Walkersville, MD (USA) / Basel, Switzerland, 25 September 2014 – Successful genome editing using ZFN, TALEN or CRISPR requires efficient delivery of such tools into the cell type of interest. Lonza's non-viral Nucleofector™ Technology has been shown to work as a reliable and sufficient method for co-transferring the required DNA- or RNA-based components into hard-to-transfect cell types. Lonza is hosting the 60-minute complimentary webinar "Genome Editing – Transfecting ZFNs, TALENs or CRISPR/Cas Using Nucleofector™ Technology" in collaboration with Sigma-Aldrich. For more details, please visit www.lonza.com/webinar-genome-editing-2014.

Lonza's Scientific Support Specialists Dr. Nazim El-Andaloussi and Dr. Claudia Schwartz will present application examples and technical tips for ZFN/CRISPR usage. They will be supported by Erika Holroyd, ZFN and CRISPR Technical Specialist, Sigma-Aldrich. Attendees will get a brief introduction to genome editing tools and learn how to make use of Nucleofector™ Technology for transfection of ZFN, TALEN or CRISPR/Cas9 system.

Researchers are invited to attend the free webinar by registering for their preferred date:

- **Tuesday, 28 October 2014 – 11 AM PDT (Los Angeles) / 2 PM EDT (New York)**
<https://attendee.gotowebinar.com/register/2788338756446660865>
- **Wednesday, 29 October 2014 – 1 PM GMT (London) / 2 PM CET (Berlin) / 9 AM EDT (New York)**
<https://attendee.gotowebinar.com/register/8963267526292647169>

The webinar lasts one hour and includes Q&A. All registrants will receive a PDF copy of the presentation and access to the recorded webinar shortly after the webinar took place. Those interested, but unable to join the webinar, please visit Lonza's Genome Editing page www.lonza.com/genome-editing for more information.

To learn more about Lonza's free webinars, please visit www.lonza.com/researchwebinars.

About Lonza Pharma&Biotech – Bioscience Solutions

Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza's bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care

Product News

companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, and complete solutions for rapid microbiology. Primary brands include BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection™, NuSieve™, PAGEr™, Poietics™ and SeaKem®.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Cologne GmbH
Marketing Communications and Product PR
Corinna König-Wildförster
Phone: +49 221 99199 464
Fax +49 221 99199 498
pr.cologne@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Phone: +41 61 316 8840
Fax: +41 61 316 9840
constance.ward@lonza.com

Product News

Additional Information and Disclaimer

Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements. Lonza Group Ltd is subject to the listing rules of the SIX Swiss Exchange, which does not have specific requirements equivalent to the listing rules of the SGX-ST for interested person transactions, acquisition and realizations and delisting.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.